Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo controlled trial

Abstract Converging lines of evidence suggest a role for facial expressions in the pathophysiology and treatment of mood disorders. To determine the antidepressant effect of onabotulinumtoxinA (OBA) treatment of corrugator and procerus muscles in people with major depressive disorder, we conducted a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of psychiatric research 2014-05, Vol.52, p.1-6
Main Authors: Finzi, Eric, Rosenthal, Norman E
Format: Article
Language:English
Subjects:
Acetylcholine Release Inhibitors - therapeutic use
Adult
Adult and adolescent clinical studies
Antidepressant
Antidepressant drugs
Biological and medical sciences
Botulinum Toxins, Type A - therapeutic use
Clinical trial
Corrugator
Depression
Depressive Disorder, Major - drug therapy
Double blind
Double-Blind Method
Female
Fishermen
Follow-Up Studies
Frowns
Humans
Logistic Models
Male
Medical sciences
Middle Aged
Miscellaneous
Mood disorders
Muscles
Neuropharmacology
OnabotulinumtoxinA
Outcome Assessment (Health Care)
Pharmacology. Drug treatments
Psychiatric Status Rating Scales
Psychiatry
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Response rate
Statistics, Nonparametric
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Converging lines of evidence suggest a role for facial expressions in the pathophysiology and treatment of mood disorders. To determine the antidepressant effect of onabotulinumtoxinA (OBA) treatment of corrugator and procerus muscles in people with major depressive disorder, we conducted a double blind, randomized, placebo-controlled trial. In an outpatient clinical research center, eighty-five subjects with DSM-IV major depression were randomized to receive either OBA (29 units for females and 40 units for males) or saline injections into corrugator and procerus frown muscles (74 subjects were entered into the analysis). Subjects were rated at screening, and 3 and 6 weeks after OBA treatment. The primary outcome measure was the response rate, as defined by ≥ 50% decrease in score on the Montgomery–Asberg Depression Rating Scale (MADRS). Response rates at 6 weeks from the date of injection were 52% and 15% in the OBA and placebo groups, respectively (Chi-Square (1) = 11.2, p  
ISSN:0022-3956
1879-1379
DOI:10.1016/j.jpsychires.2013.11.006